Search

Author/Creator Liu, Ya-Pei

1. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Issue 7 (July 2018)

Authors:
Daar, Eric S; DeJesus, Edwin; Ruane, Peter; Crofoot, Gordon; Oguchi, Godson; Creticos, Catherine; Rockstroh, Jürgen K; Molina, Jean-Michel; Koenig, Ellen; Liu, Ya-Pei; Custodio, Joseph; Andreatta, Kristen; Graham, Hiba; Cheng, Andrew; Martin, Hal; Quirk, Erin
Journal:
Lancet
Issue:
Volume 5:Issue 7(2018)
Page Start:
e347
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Long-term Efficacy and Safety of Tenofovir Disoproxil Fumarate in HIV-1-infected Adolescents Failing Antiretroviral Therapy. Issue 4 (April 2015)

Authors:
Della Negra, Marinella; Carvalho, Aroldo ProhmannDe; De Aquino, Maria Zilda; Pinto, Jorge Andrade; Da Silva, Marcos Tadeu Nolasco; Andreatta, Kristen N.; Graham, Bryan; Liu, Ya-Pei; Quirk, Erin K.
Journal:
Pediatric infectious disease journal
Issue:
Volume 34:Issue 4(2015)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Long-term Efficacy and Safety of Tenofovir Disoproxil Fumarate in HIV-1-infected Adolescents Failing Antiretroviral Therapy: The Final Results of Study GS-US-104–0321. Issue 4 (April 2015)

Authors:
Della Negra, Marinella; Carvalho, Aroldo ProhmannDe; De Aquino, Maria Zilda; Pinto, Jorge Andrade; Da Silva, Marcos Tadeu Nolasco; Andreatta, Kristen N.; Graham, Bryan; Liu, Ya-Pei; Quirk, Erin K.
Journal:
Pediatric infectious disease journal
Issue:
Volume 34:Issue 4(2015)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adults: Week 48 Results. (4th October 2017)

Authors:
Daar, Eric; DeJesus, Edwin; Ruane, Peter; Crofoot, Gordon; Oguchi, Godson; Creticos, Catherine; Rockstroh, Jurgen K; Molina, Jean-Michel; Koenig, Ellen; Liu, Ya-Pei; Andreatta, Kristen; Graham, Hiba; Cheng, Andrew; Martin, Hal; Quirk, Erin
Journal:
Open forum infectious diseases
Issue:
Volume 4(2017)Supplement 1
Page Start:
S735
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Issue 1 (January 2016)

Authors:
Mills, Anthony; Arribas, Jose R; Andrade-Villanueva, Jaime; DiPerri, Giovanni; Van Lunzen, Jan; Koenig, Ellen; Elion, Richard; Cavassini, Matthias; Madruga, Jose Valdez; Brunetta, Jason; Shamblaw, David; DeJesus, Edwin; Orkin, Chloe; Wohl, David A; Brar, Indira; Stephens, Jeffrey L; Girard, Pierr...
Journal:
Lancet infectious diseases
Issue:
Volume 16:Issue 1(2016:Jan.)
Page Start:
43
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗